Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers
Overweight and ObesityType IIb Hyperlipidaemia1 moreLow carbohydrate diet may influence the plasma lipid levels.
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin
Mixed HyperlipidemiaThe purpose of this study is to evaluate the efficacy and safety of Atorvastatin and Fenofibrate compared with atorvastatin monotherapy in mixed hypercholesterolemic patients.
Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia...
HyperlipidemiaFamilial CombinedThe purpose of this study is to evaluate the efficacy and safety of combination therapy of omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia
Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric...
Mixed HyperlipidemiaThe purpose of this study is to compare combination atorvastatin/fenofibric acid 10/135mg with atorvastatin 20mg monotherapy in the mixed hyperlipidemia who were not at lipid goals with atorvastatin 10mg monotherapy.
Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose...
DyslipidemiaStatin therapy does not fully eliminate the cardiovascular disease (CVD) risk associated with low high density lipoprotein-C (HDL-C) and high triglyceride levels. It is currently unknown what would be the best treatment option for patients with mixed hyperlipidemia who fail to meet their lipid targets with statin monotherapy at conventional does, i.e. high dose rosuvastatin or conventional statin dose plus micronized fenofibrate or conventional statin dose plus niacin/laropiprant. The aim of the present study is to compare the efficacy of high-dose rosuvastatin vs conventional statin dose plus micronized fenofibrate vs conventional statin dose plus extended-release niacin/laropiprant on lipid profile in patients with mixed hyperlipidemia. The primary efficacy endpoint will be changes in non-HDL-C levels at 6 months after treatment initiation.
Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
AtherosclerosisLeukocyte Activation Disorder2 moreIn this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.
Genetic Epidemiology of Hypertriglyceridemia
Cardiovascular DiseasesCoronary Disease3 moreTo determine prospectively the role of elevated plasma triglyceride (TG) as a risk factor for 20-year coronary heart disease (CHD) mortality in familial combined hyperlipidemia (FCHL) and familial hypertriglyceridemia (FHTG), the familial forms of hypertriglyceridemia. Also, to perform genetic epidemiologic studies of recently identified lipoprotein risk factors for CHD, including Atherogenic Lipoprotein Phenotypes (ALP) based on subclasses of low-density lipoproteins (LDL), Lipoprotein(a) (Lp(a)) and apolipoprotein (apo) B plasma levels, and apo E isoforms.
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia
AtherosclerosisCardiovascular Diseases4 moreTo conduct focused studies of lipoprotein physiology and pathophysiology in genetically characterized patients with the objectives of understanding disease mechanisms, developing better treatments, and identifying and preventing early vascular disease.
Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals
HyperlipidemiaFamilial Combined1 moreFamilial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.
Genomic Dissection of a QTL Affecting the Lipid Profile
Cardiovascular DiseasesHeart Diseases3 moreTo search for the genetic cause of the metabolic syndrome, a lipid disorder that poses a major risk for coronary heart disease.